A Study of JNJ-77242113 in Healthy Japanese and Chinese Participants

NCT05062200 | Completed Phase 1

• 2 other identifiers: CR10909777242113PSO1002
• Study Type: interventional
• Target: 36
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of JNJ-77242113 after single ascending oral dose administration as an immediate-release (IR) tablet formulation in healthy Japanese participants and after single oral dose administration as an IR tablet formulation in healthy Chinese participants; and as a delayed release (DR) tablet formulation in healthy Japanese participants.

Conditions

Healthy

Outcome Measures

Primary Outcomes (2)

• Parts 1, 2 and 3: Number of Participants with Adverse Events (AEs) as a Measure of Safety and Tolerability

  An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study.

  Up to 6 weeks

• Parts 1, 2 and 3: Plasma Concentration of JNJ-77242113

  Plasma samples will be analyzed to determine concentrations of JNJ-77242113 using a validated, specific and sensitive method.

  Predose up to 48 hours postdose (Up to Day 3)

Study Arms (4)

Cohort 1: JNJ-77242113 or Placebo (Single Ascending Dose [SAD])

EXPERIMENTAL

Japanese participants will receive single oral dose 1 of JNJ-77242113 (immediate-release \[IR\] tablet) or matching placebo on Day 1 in Cohort 1 of Part 1.

Drug: JNJ-77242113; Drug: Placebo

Cohort 2: JNJ-77242113 or Placebo (SAD)

EXPERIMENTAL

Japanese participants will receive single oral dose 2 of JNJ-77242113 (IR tablet) or matching placebo on Day 1 in Cohort 2 of Part 1.

Drug: JNJ-77242113; Drug: Placebo

Cohort 3: JNJ-77242113 or Placebo (Single Dose [SD])

EXPERIMENTAL

Chinese participants will receive single oral dose 2 of JNJ-77242113 (IR tablet) or matching placebo on Day 1 in Cohort 3 of Part 2.

Drug: JNJ-77242113; Drug: Placebo

Cohort 4: JNJ-77242113 or Placebo (SD)

EXPERIMENTAL

Japanese participants will receive single oral dose 3 of JNJ-77242113 (delayed-release \[DR\] tablet) with absorption enhancer (AbE) or matching placebo on Day 1 in Cohort 4 of Part 3.

Drug: JNJ-77242113; Drug: Placebo

Interventions

JNJ-77242113 DRUG

JNJ-77242113 will be administered as an oral tablet.

Cohort 1: JNJ-77242113 or Placebo (Single Ascending Dose [SAD]); Cohort 2: JNJ-77242113 or Placebo (SAD); Cohort 3: JNJ-77242113 or Placebo (Single Dose [SD]); Cohort 4: JNJ-77242113 or Placebo (SD)

Placebo DRUG

Matching placebo will be administered as an oral tablet.

Cohort 1: JNJ-77242113 or Placebo (Single Ascending Dose [SAD]); Cohort 2: JNJ-77242113 or Placebo (SAD); Cohort 3: JNJ-77242113 or Placebo (Single Dose [SD]); Cohort 4: JNJ-77242113 or Placebo (SD)

Eligibility Criteria

• Age: 20 Years - 60 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• For Parts 1 and 3: Japanese male or female of non-childbearing potential, who have parents and maternal and paternal grandparents who are of Japanese ethnicity
• For Part 2: Chinese male or female of non-childbearing potential, who have parents and maternal and paternal grandparents who are of Chinese ethnicity
• Healthy on the basis of physical examination, medical history, vital signs, and 12-lead electrocardiogram (ECG) performed at screening. If there are abnormalities, they must be consistent with the underlying illness in the study population. This determination must be recorded in the participant's source documents and initialed by the investigator
• Body weight not less than 50 kilograms (kg) and body mass index within the range 18 and 30 kilograms per meter square (kg/m\^2) (inclusive)
• Blood pressure (after the participant is supine for 5 minutes) between 90 and 140 millimeters of mercury (mmHg) systolic, inclusive, and no higher than 90 mmHg diastolic. If blood pressure is out of range, up to 2 repeated assessments are permitted

You may not qualify if:

• History of malignancy before screening (exceptions are squamous and basal cell carcinomas of the skin and carcinoma in situ of the cervix, or malignancy, which is considered cured with minimal risk of recurrence)
• Known allergies, hypersensitivity, or intolerance to JNJ-77242113 or its excipients
• Use of a live vaccine within 30 days prior to screening or anticipated need for a live vaccine during the study or for 30 days following the dose of study drug
• Received an experimental drug (including investigational vaccines) or used an experimental medical device within 1 month or within a period less than 10 times the drug's half-life, whichever is longer, before the dose of the study intervention is scheduled
• Test positive for human immunodeficiency virus (HIV)-1 and 2 antigen/antibodies, test positive for hepatitis C antibodies, test positive for syphilis, or test positive for hepatitis B virus (HBV) infection at screening

Sponsors & Collaborators

• Janssen Pharmaceutical K.K.: lead

Study Sites (1)

Souseikai Hakata Clinic

Fukuoka, 812-0025, Japan

Location

Study Officials

• Janssen Pharmaceutical K.K., Japan Clinical Trial

  Janssen Pharmaceutical K.K.

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Purpose: TREATMENT
• Intervention Model: SEQUENTIAL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 21, 2021
• First Posted: September 30, 2021
• Study Start: October 25, 2021
• Primary Completion: September 28, 2022
• Study Completion: September 28, 2022
• Last Updated: February 3, 2025

Record last verified: 2025-01

Data Sharing

• IPD Sharing: Will share

Locations

JP (1)